Role of the p16 tumor suppressor gene in cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1197-1206

  Liggett Jr , William H ^a   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER; CANCER GROWTH; CARCINOGENESIS; DNA METHYLATION; FAMILIAL CANCER; GENE DELETION; HUMAN; MELANOMA; NONHUMAN; POINT MUTATION; PRECANCER; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0344301900     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1197     Document Type: Article

References (133)

1. Heichman KA, Roberts JM: Rules to replicate by. Cell 79:557-560, 1994
2. Hunter T, Pines J: Cyclins and cancer II: Cyclin D and CDK inhibitors come of age. Cell 79:573-576, 1994
3. Hall M, Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv Cancer Res 68:67-108, 1996
4. Nobori T, Miura K, Wu DJ, et al: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
5. Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially involved in the genesis of many tumor types. Science 264:436-437, 1994
6. Cairns P, Mao L, Merlo A, et al: Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science 265:415-417, 1994
7. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707, 1993
8. Spruck CH III, Gonzalez-Zulueta M, Shibata A, et al: p16 gene in uncultured tumors. Nature 370:183-184, 1994
9. Goldstein AM, Dracopoli NC, Engelstein M, et al: Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p and evidence for genetic heterogeneity. Am J Hum Genet 54:489-496, 1994
10. MacGeoch C, Bishop JA, Bataille V, et al: Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 3:2195-2200, 1994
11. Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial melanoma. Nature Genet 8:15-21, 1994
12. Gruis NA, van der Velden PA, Sandkuijl LA, et al: Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 10:351-353, 1995
13. INK4a mutations. N Engl J Med 333:970-974, 1994
14. Cairns P, Tokino K, Eby Y, et al: Homozygous deletion of 9p21 in primary human bladder tumors detected by comparative multiple polymerase chain reaction. Cancer Res 54:1422-1424, 1994
15. Cairns P, Poladcik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/CDKN2 in primary human tumors. Nature Genet 11:210-212, 1995
16. Giani C, Finocchiaro G: Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res 54:6338-6339, 1994
17. Jen J, Harper JW, Bigner SH, et al: Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353-6358, 1994
18. Ueki K, Rubio M-P, Ramesh V, et al: MTS1/CDKN2 gene mutations are rare in primary human astrocytomas with allelic loss of chromosome 9p. Hum Mol Genetics 10:1841-1845, 1994
19. Dreyling MH, Bohlander SK, Adeyanju MO, et al: Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization. Cancer Res 55:984-988, 1995
20. Kyritsis AP, Zhang B, Zhang W, et al: Mutations of the p16 gene in gliomas. Oncogene 12:63-67, 1996
21. Li Y-J, Hoang-Xuan K, Delattre J-Y, et al: Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas. Oncogene 11:597-600, 1995
22. Moulton T, Samara G, Chung W-Y, et al: MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme. Am J Path 146:613-619, 1995
23. Ueki K, Ono Y, Henson JW, et al: CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 56:150-153, 1996
24. Walker DG, Duan W, Popovic EA, et al: Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas. Cancer Res 55:20-23, 1995
25. Costello JF, Berger MS, Huang H-JS, et al: Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation. Cancer Res 56:2405-2410, 1996
26. Saxena A, Robertson JT, Ali IU: Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas. Oncogene 13:661-664, 1996
27. Tsuzuki T, Tsunoda S, Sakaki T, et al: Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas. Cancer 78:287-293, 1996
28. Zhang S-Y, Klein-Szanto AJP, Saute ER, et al: Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994
29. Lydiatt WM, Murty VVVS, Davidson BJ, et al: Homozygous deletions and loss of expression of the CDKN2 gene occur frequently in head and neck squamous cell carcinoma cell lines but infrequently in primary tumors. Genes Chromosom Cancer 13:94-98, 1995
30. Reed A, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633, 1996
31. Heinzel PA, Balaram P, Bernard H-U: Mutations and polymorphisms in the p53, p21, and p16 genes in oral carcinomas of Indian betel quid chewers. Int J Cancer 68:420-423, 1996
32. Mori T, Miura K, Aoki T, et al: Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinomas. Cancer Res 54:3396-3397, 1994
33. Okamoto A, Demetrick DJ, Spillane EA, et al: Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994
34. Esteve A, Martel-Planche G, Sylla BS, et al: Low frequency of p16/CDKN2 gene mutations in esophageal carcinomas. Int J Cancer 66:301-304, 1996
35. Maesawa C, Tamura G, Nishizuka S, et al: Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma. Cancer Res 56:3875-3878, 1996
36. Zhou X, Tarmin L, Yin J, et al: The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9:3737-3741, 1994
37. Caldas C, Hahn SA, da Costa LT, et al: Frequent somatic mutations and homozygous deletions of the p16 (MTS-1) gene in pancreatic adenocarcinoma. Nature Genet 8:27-32, 1994
38. Bartsch D, Shevlin DW, Tung WS, et al: Frequent mutations of CDKN2 in primary pancreatic adenocarcinomas. Genes Chromosom Cancer 14:189-195, 1995
39. Huang L, Goodrow TL, Zhang S-Y, et al: Deletion and mutation analyses of the p16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas. Cancer Res 56:1137-1141, 1996
40. Orlow I, Lacombe L, Hannon GJ, et al: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87:1524-1529, 1995
41. Gonzales-Zulueta M, Bender CM, Yang AS, et al: Methylation of the 5′ CpG island of the p16/CDNKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55:4531-4535, 1995
42. Packenham JP, Taylor JA, Anna CH, et al: Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors. Mol Carcinog 14:147-151, 1995
43. Williamson MP, Elder PA, Shaw ME, et al: p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet 4:1569-1577, 1995
44. Cheng JQ, Jhanwar SC, Klein WM, et al: p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547-5551, 1994
45. Xiao S, Li D, Vijg J, et al: Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 11:511-515, 1995
46. INK4B) display frequent homozygous deletions in primary cells from T- but not B-cell lineage acute lymphocytic leukemias. Blood 84:4038-4044, 1994
47. Ogawa S, Hirano N, Sato N, et al: Homozygous loss of the cyclin-dependent kinase 4-inhibitor (p16) gene in human leukemias. Blood 84:2431-2435, 1994
48. INK4A/MTS1) gene structure and expression in acute lymphoblastic leukemias. Leukemia 9:1240-1245, 1995
49. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 55:1436-1440, 1995
50. Quesnel B, Preudhomme C, Philippe N, et al: p16 gene homozygous deletions in acute lymphoblastic leukemia. Blood 85:657-663, 1995
51. Sill H, Goldman JM, Cross NCP: Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 85:2013-2016, 1995
52. Stranks G, Height SE, Mitchell D, et al: Deletions and rearrangement of CDKN2 in lymphoid malignancy. Blood 85:893-901, 1995
53. Cayuela J-M, Madani A, Sanhes L, et al: Multiple tumor-suppressor gene 1 inactivation is the most frequent genetic alteration in T-cell acute lymphoblastic leukemia. Blood 85:2180-2186, 1996
54. Guidal-Giroux C, Gerard B, Cave H, et al: Deletion mapping indicates that MTS1 is the target of frequent deletions at chromosome 9p21 in paediatric acute lymphoblastic leukaemias. Br J Haematol 92:410-419, 1996
55. INK4 gene. Blood 87:1657-1658, 1996
56. INK4A and p18, in childhood T-cell lineage acute lymphoblastic leukemias. Leukemia 10:255-260, 1996
57. Nakao M, Yokota S, Kaneko H, et al: Alterations of CDKN2 gene structure in childhood acute lymphoblastic leukemia: Mutations of CDKN2 are observed preferentially in T-lineage. Leukemia 10:249-254, 1996
58. Sill H, Aguiar RCT, Schmidt H, et al: Mutational analysis of the p15 and p16 genes in acute leukaemias. Br J Haematol 92:681-683, 1996
59. Ohnishi H, Hanada R, Horibe K, et al: Homozygous deletions of p16/MTS1 and p15/MTS2 genes are frequent in t(1;19)-negative but not in t(1;19)-positive B precursor acute lymphoblastic leukemia in childhood. Leukemia 10:1104-1110, 1996
60. Uchida T, Kinoshita T, Watanabe T, et al: The CDKN2 gene alterations in various types of adult T-cell leukaemia. Br J Haematol 94:665-670, 1996
61. Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 55:4525-4530, 1995
62. Hayashi N, Sugimoto Y, Tsuchiya E, et al: Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small-cell lung carcinomas. Biochem Biophys Res Comm 202:1426-1430, 1994
63. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res 55:1448-1451, 1995
64. INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995
65. Washimi O, Nagatake M, Osada H, et al: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small-cell lung cancers. Cancer Res 55:514-517, 1995
66. Xiao S, Li D, Corson JM, et al: Codeletion of p15 and p16 genes in primary non-small-cell lung carcinoma. Cancer Res 55:2968-2971, 1995
67. Okami K, Cairns P, Westra W, et al: Detailed deletion mapping at chromosome 9p21 in non-small-cell lung cancer by microsatellite analysis and fluorescence in situ hybridization. Int J Cancer (submitted).
68. Ohta M, Nagai H, Shimizu M, et al: Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 54:5269-5272, 1994
69. INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res 56:5023-5032, 1996
70. Schultz DC, Vanderveer L, Buetow KH, et al: Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance of 9q and rare alterations involving 9p including CDKN2. Cancer Res 55:2150-2157, 1995
71. Ichikawa Y, Yoshida S, Koyama Y, et al: Inactivation of p16/CDKN2 and p15/MTS2 genes in different histological types and clinical stages of primary ovarian tumors. Int J Cancer 69:466-470, 1996
72. Schuyer M, van Staveren IL, Klijn JGM, et al: Sporadic CDKN2 (MTS1/p16INK4) gene alterations in human ovarian tumors. Brit J Cancer 74:1069-1073, 1996
73. Fujita M, Enomoto T, Haba T, et al: Alteration of p16 and p15 genes in common epithelial ovarian tumors. Int J Cancer 74:148-155, 1997
74. INK4a gene product in human pituitary tumors. Cancer Res 56:2493-2496, 1996
75. Maelandsmo GM, Berner J-M, Florenes VA, et al: Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas - Relationship to amplification and mRNA levels of CDK4 and CCND1. Br J Cancer 72:393-398, 1995
76. Iolascon A, Faienza MF, Coppola B, et al: Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosom Cancer 15:217-222, 1996
77. Miller CW, Aslo A, Campbell MJ, et al: Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86:136-142, 1996
78. Wu M-S, Lin Y-W, Sheu J-C, et al: Intragenic homozygous deletions of MTS1 gene in gastric cancer in Taiwan. Jpn J Cancer Res 87:1052-1055, 1996
79. Parker SL, Tong T, Bolden S, et al: Cancer statistics, 1997. CA Cancer J Clin 47:5-27, 1997
80. Hollstein M, Rice K, Greenblatt MS, et al: Data base of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555, 1994
81. INK4A transcript. Cancer Res 55:2995-2997, 1995
82. Stone S, Jiang P, Dayananth P, et al: Complex structure and regulation of the p16 (MTS1) locus. Cancer Res 55:2988-2994, 1995
83. Coleman A, Fountain JW, Nobori T, et al: Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia. Cancer Res 54:344-348, 1994
84. Sidransky D: Two tracks but one race? Cancer Genet Curr Biol 6:523-525, 1996
85. ARF. Proc Natl Acad Sci USA 94:669-673, 1997
86. Arap W, Knudsen E, Sidransky D, et al: Functional analysis of wild-type and malignant glioma-derived CDKN2A β alleles: Evidence for an RB-independent growth suppressive pathway. (Submitted, 1997).
87. Bird A: The essentials of DNA methylation. Cell 70:5-8, 1992
88. Migeon BR: Insights into X chromosome inactivation from studies of species variation, DNA methylation and replication, and vice versa. Genet Res 56:91-98, 1990
89. Li E, Beard C, Jaenisch R: Role for DNA methylation in genomic imprinting. Nature 366:362-365, 1993
90. Herman JG, Latif F, Weng Y, et al: Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 91:9700-9704, 1994
91. Sakai T, Toguchida J, Ohtani N, et al: Allele-specific hypermethylation of the retinoblastoma tumor suppressor gene. Am J Hum Genet 48:880-888, 1991
92. Merlo A, Herman JG, Mao L, et al: 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor CDKN2/p16 in human cancers. Nature Med 7:686-692, 1995
93. INK4/MTS1 gene by a chromosome translocation t(9;14)(p21-22;q11) in an acute lymphoblastic leukemia of B-cell type. Cancer Res 56:848-854, 1996
94. Koff A, Cross F, Fisher J, et al: Human cyclin E: A new cyclin that interacts with two members of the CDC2 gene family. Cell 66:1217-1228, 1991
95. Lew DJ, Dulic V, Reed SI: Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) function in yeast. Cell 66:1197-1206, 1991
96. Ohtsubo M, Roberts JM: Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 259:1908-1912, 1993
97. Quelle DE, Ashman RA, Shurtleff SA, et al: Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev 7:1559-1571, 1993
98. Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995
99. Sherr CJ: Cancer cell cycles. Science 274:1672-1677, 1996
100. Nevins JR: E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429, 1992
101. Xiong Y, Zhang H, Beach D: Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 7:1572-1583, 1993
102. Parry D, Bates S, Mann DJ, et al: Lack of cyclin D-CDK complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumor suppressor gene product. EMBO J 14:503-511, 1995
103. Hirai H, Roussei MF, Kato J-Y, et al: Novel INK4 proteins, p19 and p18 are specific inhibitors of cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 15:2672-2681, 1995
104. Arap W, Nishikawa R, Furnari FB, et al: Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55:1351-1354, 1995
105. INK4 gene mediated by an adenovirus vector. Cancer Res 55:3250-3253, 1995
106. Koh J, Enders GH, Dynlacht BD, et al: Tumor-derived p16 alleles encoding proteins defective in cell cycle inhibition. Nature 375:506-510, 1995
107. CDKN2 tumour suppressor. Nature 375:503-506, 1995
108. INK4A inactivation in non-small-cell lung cancer cell lines. Cancer Res 55:6200-6209, 1995
109. Quelle DE, Zindy F, Ashman RA, et al: Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000, 1996
110. Liggett WH Jr, Sewell DA, Rocco J, et al: p16 and p16β are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Res 56:4119-4123, 1996
111. INK/MTS2- related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 8:2939-2952, 1994
112. Medema RH, Herrera RE, Lam F, et al: Growth suppression by p16/Ink4 requires functional retinoblastoma protein. Proc Natl Acad Sci USA 92:6289-6293, 1995
113. Beijersbergen RL, Kerkhoven RM, Zhu L, et al: E2F-4, a new member of the E2F gene family has oncogenic activity and associates with p107 in vivo. Genes Dev 8:2680-2690, 1994
114. Cobrink D, Whyte P, Peeper DS, et al: Cell cycle-specific association of E2F with the p130 E1A-binding protein. Genes Dev 7:2392-2404, 1993
115. Lees JA, Sito M, Vidal M, et al: The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 13:7813-7825, 1993
116. Sewell DA, Liggett WH Jr, Yarborough WG, et al: Human p16β encodes a novel 14 kd protein and suppresses growth in vitro independently from pRB. Proc Am Assoc Can Res 38:80, 1997 (abstr)
117. Knudson AG Jr: Mutation and cancer. Statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823, 1971
118. Wang TC, Cardiff RD, Zukerberg L, et al: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:699-671, 1994
119. Sicinski P, Donaher JL, Parker SB, et al: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621-630, 1995
120. Costello JF, Plass C, Arap W, et al: Cyclin-dependent kinase 6 (CDK6) amplification in human gliomas identified using two-dimensional separation of genomic DNA. Cancer Res 57:1250-1254, 1997
121. INK4a binging domain of CDK4 in familial melanoma. Nature Genet 12:97-99, 1996
122. Khatib ZA, Matsushime H, Valentine M, et al: Coamplification of the CDK4 gene with MDM2, and GLI in human sarcomas. Cancer Res 53:5535-5541, 1993
123. Reifenberger G, Reifenberger J, Ichimura K, et al: Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 54:4299-4303, 1994
124. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nature Med 3:313-319, 1997
125. Robles MTS, Symonds H, Chen J, et al: Induction versus progression of brain tumor development: Differential functions for the pRB- and p53- targeting domains of simian virus 40 T antigen. Mol Cell Biol 14:2686-2698, 1994
126. Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759-767, 1990
127. Califano J, van der Riet P, Westra W, et al: Genetic progression model for head and neck cancer: Implications for field cancerization. Cancer Res 56:2488-2492, 1996
128. Reznikoff CA, Yeager TR, Belair CD, et al: Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6. but not E7, transformed human uroepithelial cells. Cancer Res 56:2886-2890, 1996
129. Alcorta DA, Xiong Y, Phelps D, et al: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93:13742-13747, 1996
130. Hara E, Smith R, Parry D, et al: Regulation of p16 CDKN2 expression and its implication for cell immortalization and senescence. Mol Cell Biol 16:859-867, 1996
131. 1cdk2 complexes. Proc Natl Acad Sci USA 90:11034-11038, 1993
132. INK4a. Cell 88:593-602, 1997
133. Serrano M, Lee H-W, Chin L, et al: Role of the Ink4a locus in tumor suppression and cell mortality. Cell 85:27-37, 1996